Full attention: As adults become more commonly diagnosed with ADHD, industry revenue is expected to rise
ADHD Medication Manufacturing The ADHD Medication Manufacturing industry has exhibited steady growth over the five years to 2019, driven by the continued growth in the incidence of ADHD. However, revenue growth has slowed significantly compared with its extreme growth in the late 2000s. This can partially be attributed to expiring patents and increased competition from generic drugs, creating downward pressure on prices and restricting industry profit. However, total health expenditure is forecast to increase more quickly over the next five years as insurance coverage improves. The adult market will continue to grow as adult usage of ADHD medications increases. Additionally, the number of children aged 9 and younger is forecast to increase, bolstering the number of ADHD diagnoses, as ADHD is typically first diagnosed in young children.
Operators in this industry manufacture medications that treat people with attention deficits, such as attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD).
This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.
Our reports have been used by over 10K customers, including:
“Pompe Disease – Pipeline Insight, 2020,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Pompe Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration,...